Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia

Published on February 3, 2021

This interim analysis of the phase 3 trial of Gam-COVID-Vac showed 91·6% efficacy against COVID-19 and was well tolerated in a large cohort. The Lancet

Other news

Antimicrobial resistance training curriculum: Training Social Scientists on the Social dimensions of AMR

February 3, 2021
The Special-SOC AMR (antimicrobial resistance) training curriculum is an intended resource for trainers who aim to provide a high-level training on the relevance of social sciences in AMR to scholars or professionals with a university level social science background. Sonar- Global

Updating WHO’s global strategy for malaria

February 3, 2021
Representatives from malaria-affected countries and partner organizations gathered on 28 January in a WHO virtual forum to share feedback and perspectives on the Global technical strategy for malaria 2016-2030.  Inputs from a diverse group of stakeholders will be reflected in an updated strategy, which will be published in June 2021. WHO